In patients receiving radiotherapy for newly diagnosed metastatic prostate cancer, bone metastasis count and location are associated with overall and failure-free survival, according to an exploratory analysis of the phase 3 STAMPEDE trial. "Prostate radiotherapy improves survival in men with low-burden metastatic prostate cancer," write the investigators in their publication in JAMA Oncology, led by first author Adnan Ali, MBBS, Clinical Research Fellow in the Division of Cancer Sciences at the...
According to research now published in JAMA Oncology, magnetic resonance imaging (MRI) with targeted biopsy (MRI-targeted biopsy) was shown to be just as effective at detecting prostate cancer compared with systematic 12-core transrectal ultrasonography (TRUS) biopsy. For this multicenter, prospective, randomized study, led by Laurence Klotz, MD, FRCSC, affiliate scientist at Sunnybrook Health Sciences Centre of the University of Toronto, 453 biopsy-naive patients with clinically suspected prost...
In patients with low-risk prostate cancer, the use of an active surveillance approach is significantly impacted by geographic location, according to a study recently published in JAMA Network Open. In this interview with i3 Health, Samuel L. Washington III, MD, MAS, Assistant Professor of Urology at the University of California San Francisco and the study's lead author, discusses the significance of these results and suggests ways to reduce variation in the use of active surveillance, thereby op...
The FDA has added new overall survival and other secondary outcome data to the prescribing information for darolutamide (Nubeqa®, Bayer), an androgen receptor inhibitor which was approved for the treatment of nonmetastatic castration-resistant prostate cancer (CRPC) in 2019. The updates were based on the final analysis of the phase 3 ARAMIS trial (NCT02200614), led by first author Karim Fizazi, MD, Head of the Department of Cancer Medicine at the Institut Gustave Roussy in Villejuif, France. The...
Relugolix (OrgovyxTM, Myovant Sciences) was recently FDA approved as the first oral hormone therapy for patients with advanced prostate cancer. In this interview, Neal Shore, MD, FACS, Medical Director of the Carolina Urologic Research Center and lead investigator of the HERO trial, on which the approval was based, speaks with i3 Health about the approval's significance and the future of treatment for patients with this disease. Can you comment on the significance of the approval of relugolix fo...